Last reviewed · How we verify
Sex hormones and modulators of the genital system.
Sex hormones and modulators of the genital system. is a Small molecule drug developed by Fundacion Clinic per a la Recerca Biomédica. It is currently FDA-approved.
The drug, a sex hormone and modulator of the genital system, is currently marketed by Fundacion Clinic per a la Recerca Biomédica. A key strength is the protection provided by the key composition patent, which expires in 2028. The primary risk is the lack of disclosed revenue data, which may affect investment and market valuation.
At a glance
| Generic name | Sex hormones and modulators of the genital system. |
|---|---|
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sex hormones and modulators of the genital system. CI brief — competitive landscape report
- Sex hormones and modulators of the genital system. updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI